News · 18 November 2026

FDA clears first at-home shot for thyroid eye disease

18 November 2026 · US · Health · US · Uplifting

FDA clears first at-home shot for thyroid eye disease
Picture: Medscape · Medscape lead image · unknown

Roche won FDA approval to market satralizumab (Enspryng) as the first at-home subcutaneous treatment for adults with thyroid eye disease. The decision followed phase 3 SatraGO data showing a 52.9 percent proptosis response and a 60.7 percent diplopia reduction versus placebo in SatraGO-2 among patients with active disease. The drug blocks interleukin-6 receptors.

Where this came from. 2 outlets reported this. We read them, then wrote the sixty words above.

Also on 18 November 2026